Get Your Treatments Recommended by AIPharma AI Visibility

74% of pharma/biotech orgs actively use AI (NVIDIA 2026). Our AI visibility tracking monitors how AI recommends your drugs. Pfizer leads with 16.4% AI citation share. Track your AI SOV before competitors claim it.

Yes. Over 50% of HCPs use AI assistants professionally (Elsevier 2025), with 70% of interactions happening outside clinic hours (OpenAI 2026). Use prompt research to discover what clinicians ask about your drugs and ensure AI displays accurate dosage, indications, and safety data.

AI is the new "front door" for medical information. ChatGPT drives 83.8% of healthcare AI referral traffic. Monitor with bot traffic analysis to understand how AI indexes your clinical data and PI documents.

Yes. Benchmark your AI SOV against Pfizer (16.4% per Conductor 2026), Roche, Novartis, and others. Track across ChatGPT, Perplexity, and Gemini (21.5% share) for complete visibility.

Yes. The AI clinical trials market reached $3.8B in 2025 (BCC Research) ($5.5B projected 2026). AI improves trial recruitment up to 65%. Track citations with our report builder.

ChatGPT (64–84% share), Gemini (21.5%), Perplexity (7.8%), Copilot (4.7%). Domain-specific AI tools grew 7x to 22% adoption in 2025.

EU AI Act high-risk provisions take effect Aug 2, 2026. FDA/EMA established joint AI principles in Jan 2026. Track how AI represents your drug claims. Watch our demo for compliance features.

Yes. German data hosting, SOC 2, enterprise-grade security. AI companies captured 55% of all health tech funding in 2025 (Bessemer 2026). Enterprise plans include LLMOps audit logs and traceability.

GEO ensures your drug information is structured so AI platforms can cite it accurately. This includes schema markup, factual claims with source attribution, and clinical data formatting. Our GEO audit shows exactly what AI can and can't read from your current content.

Finseo tracks all mentions of your brand and products across AI platforms, including when they appear in unexpected therapeutic contexts. Use prompt research to discover the actual prompts where your drug surfaces, so medical affairs can respond to emerging AI narratives.

Traditional monitoring covers news and social media. Finseo specifically tracks what AI models say when clinicians and patients ask questions. That channel didn't exist two years ago but now reaches over 50% of HCPs (Elsevier 2025). It's not media monitoring, it's algorithmic visibility tracking.

Yes. Pharma companies with multiple therapeutic areas, brands, or regional subsidiaries can track each one independently. Enterprise plans support multi-workspace setups with role-based access, so each brand team sees only their data.